Epstein–Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation
暂无分享,去创建一个
A. Levis | A. Rocchetti | M. Pini | A. Baraldi | F. Salvi | F. Zallio | S. Tamiazzo | Franca Gotta | M. Corsetti | V. Primon | Claudia Bertassello | Valeria Primon
[1] H. Heslop,et al. T-cell therapy in the treatment of post-transplant lymphoproliferative disease , 2012, Nature Reviews Clinical Oncology.
[2] D. Dvořáková,et al. Monitoring of Epstein–Barr virus load in patients after allogeneic hematopoietic stem cell transplantation , 2012, Infection.
[3] K. Naresh,et al. Posttransplant Lymphoproliferative Disorders , 2012, Advances in hematology.
[4] M. Pronicki,et al. Epstein–Barr virus DNA load in peripheral blood mononuclear cells and whole blood from pediatric transplant recipients , 2011, Transplant infectious disease : an official journal of the Transplantation Society.
[5] A. Ibatici,et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] P. Chevallier,et al. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation , 2011, Leukemia.
[7] P. Ljungman. Molecular monitoring of viral infections after hematopoietic stem cell transplantation , 2010, International journal of hematology.
[8] H. Heslop. How I treat EBV lymphoproliferation. , 2009, Blood.
[9] H. Einsele,et al. Outcome of treatment of Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[10] M. Boeckh,et al. How we treat cytomegalovirus in hematopoietic cell transplant recipients. , 2009, Blood.
[11] E. Jaffe,et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. , 2009, Blood.
[12] P. Martiat,et al. Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation , 2009, Transplantation.
[13] F. Baldanti,et al. Kinetics of Epstein-Barr Virus DNA Load in Different Blood Compartments of Pediatric Recipients of T-Cell-Depleted HLA-Haploidentical Stem Cell Transplantation , 2008, Journal of Clinical Microbiology.
[14] K. Hedman,et al. Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. , 2007, Haematologica.
[15] D. Weinstock,et al. Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development , 2006, Bone Marrow Transplantation.
[16] V. Levitsky,et al. Epidemiology of acute promyelocytic leukemia , 1995 .
[17] G. Palù,et al. The real‐time polymerase chain reaction‐guided modulation of immunosuppression enables the pre‐emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation , 2005, British journal of haematology.
[18] H. Heslop,et al. Post-transplant lymphoproliferative disorders. , 2005, Annual review of medicine.
[19] R. Krance,et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.
[20] B. van der Holt,et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.
[21] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[22] M. Nieminen,et al. Malignancies after heart transplantation: presence of Epstein–Barr virus and cytomegalovirus , 2001, Clinical transplantation.
[23] Jaap M Middeldorp,et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. , 2001, Blood.
[24] I. Ernberg,et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.
[25] A. Osterhaus,et al. Development of a Real-Time Quantitative Assay for Detection of Epstein-Barr Virus , 2000, Journal of Clinical Microbiology.
[26] E. Jaffe,et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.
[27] J. Torre-Cisneros,et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. , 1997, The Journal of infectious diseases.